RESEARCHERS have raised hopes of new treatments for patients with chronic kidney disease after uncovering fresh insights into a protein that causes damage in kidneys and hearts.

In a study in mice, scientists found that scarring in kidneys and hearts was driven by a protein called Indian Hedgehog (IHH), which is produced and released by a subset of cells in aged and injured kidneys.

Experts say further studies are needed to explore IHH as a potential target for therapies to treat chronic kidney disease (CKD) – a condition that affects 10 per cent of the world’s population.

READ MORE: Kidney transplant and dialysis patients see mortality risk slashed 

CKD is a term used to cover any form of kidney disease that continues for more than a few months.

It can affect people of any age, but older people are more likely to experience some level of CKD.

While CKD primarily causes damage to kidneys, it is also a major risk factor for accelerated cardiovascular disease and premature death.

Progressive fibrosis – scarring of the kidneys – is a common feature in all CKD, but the mechanism underlying this connection is not fully understood.


📝 Sign up for the Inside the NHS newsletter where each week our health correspondent Helen McArdle exclusively breaks down vital statistics, issues in healthcare and provides a platform to those on the NHS frontlines who are too reluctant to speak publicly. Click here to sign up! 👈


Research carried out by scientists at Edinburgh University has now identified a subset of epithelial cells – cells which make up body tissue – that produce IHH and are only present within aged or injured mouse kidneys.

They demonstrated that these cells produced IHH in response to being activated by another protein called TNF, which is well-recognised as a driver of inflammation.

When blocking the actions of TNF or IHH in mouse models of kidney scarring, the team found that scar production in the kidney was reduced and kidney function was also better preserved.

READ MORE: Mild kidney disease linked to increased risk of cancer 

Increased levels of scarring in the heart also returned to normal levels.

In humans, the team showed that circulating IHH levels were significantly raised in patients with CKD.

Patients with cardiovascular disease also had higher levels of IHH than those without cardiac problems.

The findings offer hope that blocking the TNF/IHH signalling pathway could improve both kidney and heart fibrosis problems – the leading cause of morbidity and mortality in patients with CKD.

Dr David Ferenbach, an expert in renal medicine at Edinburgh University who was the senior author on the study, said: “There is a major unmet need for better treatments to halt the progressive kidney scarring and cardiovascular problems which affect so many patients with CKD.

"I’m excited at the potential of this work, and the new insights to be gained into the role of IHH as a major driver of multi-organ fibrosis, which we hope can be a first step on the road towards better treatments for patients.”

READ MORE: Heart attacks can be diagnosed more accurately using AI tool 

The study, published in the journal Science Translational Medicine, was funded by Kidney Research UK, the Wellcome Trust and the Medical Research Council UK.